Group 1 - The global in vitro diagnostics (IVD) market is projected to grow from $66.7 billion in 2018 to $186.1 billion by 2030, with a compound annual growth rate (CAGR) of 8.9% [1][2] - China's IVD industry has experienced rapid development and is transitioning into an upgrade and replacement phase, with diverse diagnostic technologies such as biochemical, immunological, POCT, molecular, and pathological diagnostics [2][3] - The market for immunodiagnostics in China is expected to grow from 37.3 billion yuan in 2021 to 50.3 billion yuan in 2023, with a CAGR of 16.13% [2] Group 2 - The biochemical diagnostics market in China is competitive, with domestic products holding over 70% market share, and the market size is projected to grow from 17.1 billion yuan in 2021 to 19.0 billion yuan in 2023, with a CAGR of 5.41% [3] - The POCT market in China is anticipated to grow from 11.2 billion yuan in 2021 to 16.0 billion yuan in 2023, with a CAGR of 19.52%, driven by the convenience of POCT applications and increased demand for rapid pathogen testing [3] - The molecular diagnostics market in China, while starting later, has reached a scale exceeding 10 billion yuan, supported by rising demand for precision medicine, technological advancements, and favorable national policies [3][4] Group 3 - The Chinese pathogen microbiological diagnostics market is projected to grow from 16.82 billion yuan in 2018 to 90.27 billion yuan by 2030, with a CAGR of 15.0% [4] - Companies to watch in the IVD sector include Mindray Medical (300760.SZ), New Industries (300832.SZ), Antu Bio (603658.SH), YHLO (688575.SH), Dirui Medical (300396.SZ), and Adeept Bio (300685.SZ) [4]